title: Better documentation through standardized forms: what progress have we made since the 1800s?
abstract: It has been over a century since allergy skin testing and immunotherapy were first utilized. Both have withstood the test of time and numerous challenges such as cromolyn, antihistamines, and leukotriene modifiers that have threatened to make them obsolete, to continue to play a prominent role in the diagnosis and treatment of the allergic patient. Considerable advances in the understanding of immunotherapy mechanisms and effective allergen dosing as well as improved extract quality have been made in recent years. However, there appears to be a lag in the widespread implementation of these advances into clinical practice, where a broad wide range of practice patterns exists. The wide diversity of allergy practice patterns is likely because of the absence of a uniform curriculum in allergy and immunology training programs. Recently, practice parameters have been developed by the American Academy of Allergy, Asthma and Immunology' Immunotherapy Committee and the Joint Task Force on Practice Parameters, an organization that represents the American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology, aimed at promoting a consistent, objective scientific approach to allergy skin testing and immunotherapy. Standardized allergy skin test and immunotherapy forms were designed to incorporate these guidelines. The following article summarizes the recommendations of the practice parameters and reviews some of the clinical evidence that lends support to these guidelines, which are intended to enhance the safety and efficacy of allergy skin testing and immunotherapy.
authors.affiliation: Nova Southeastern University Ostheopathic School of Medicine, Allergy Asthma Center, Fort Lauderdale, Florida 33334, USA.
authors.forename: Linda
authors.initials: L
authors.lastname: Cox
mesh_terms: D000485:Allergens / Q000494:pharmacology*; D000486:Allergy and Immunology / Q000592:standards* / Q000639:trends; D003888:Desensitization, Immunologic / Q000009:adverse effects / Q000379:methods; D004282:Documentation / Q000592:standards* / Q000639:trends; D005260:Female; D005544:Forecasting; D005568:Forms and Records Control; D006801:Humans; D006967:Hypersensitivity / Q000175:diagnosis* / Q000628:therapy; D007167:Immunotherapy / Q000379:methods; D008297:Male; D008499:Medical Records / Q000592:standards*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012882:Skin Tests / Q000009:adverse effects / Q000379:methods*; D017749:Total Quality Management; D014481:United States
chemical_list: D000485:Allergens